Cumberland Pharmaceuticals (CPIX) Equity Average (2016 - 2025)
Cumberland Pharmaceuticals (CPIX) has disclosed Equity Average for 15 consecutive years, with $25.3 million as the latest value for Q4 2025.
- Quarterly Equity Average rose 7.06% to $25.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $25.3 million through Dec 2025, up 7.06% year-over-year, with the annual reading at $23.7 million for FY2025, 9.05% down from the prior year.
- Equity Average hit $25.3 million in Q4 2025 for Cumberland Pharmaceuticals, down from $26.9 million in the prior quarter.
- In the past five years, Equity Average ranged from a high of $47.3 million in Q2 2021 to a low of $23.7 million in Q4 2024.
- Historically, Equity Average has averaged $34.7 million across 5 years, with a median of $36.1 million in 2023.
- Biggest five-year swings in Equity Average: tumbled 30.34% in 2024 and later grew 7.06% in 2025.
- Year by year, Equity Average stood at $44.6 million in 2021, then decreased by 16.12% to $37.4 million in 2022, then dropped by 13.29% to $32.5 million in 2023, then decreased by 27.1% to $23.7 million in 2024, then increased by 7.06% to $25.3 million in 2025.
- Business Quant data shows Equity Average for CPIX at $25.3 million in Q4 2025, $26.9 million in Q3 2025, and $28.0 million in Q2 2025.